Ajanta Pharma has received a certificate confirming compliance with SEBI regulations concerning depositories and participants for the quarter ended September 30, 2025. The confirmation was received from MUFG Intime India Private Limited, the Registrar and Share Transfer Agent. This certificate confirms the dematerialization of shares and adherence to regulatory guidelines, ensuring investor protection.
Confirmation of Depository Compliance
Ajanta Pharma has received confirmation regarding compliance with depository regulations. The certificate, provided by MUFG Intime India Private Limited, covers the quarter ending September 30, 2025. This confirms that all securities received for dematerialization have been duly processed.
Details of Compliance
The certificate confirms that the securities received from depository participants for dematerialization during the quarter ending September 30, 2025, were duly processed and confirmed. Additionally, it verifies that the security certificates received for dematerialization were mutilated and canceled after verification, with the depositories’ names substituted in the register of members within the prescribed timelines. This ensures adherence to regulatory standards and proper record-keeping of share ownership.
MUFG Intime India Confirmation
MUFG Intime India Private Limited, the Registrar and Share Transfer Agent, has confirmed that securities have been listed on the stock exchanges where the earlier issued securities are listed. This ensures compliance with listing requirements.
Source: BSE
